THE ROLE OF THE LIVER AS AN ENDOCRINE GLAND
Keywords:
liver, endocrine function, hepatocyte, hepatokine, IGF-1, hepcidin, thrombopoietin, FGF21, angiotensinogen, fetuin-A, hormone metabolism, liver cirrhosis.Abstract
The liver, in addition to being the body's principal metabolic organ, plays an important role in endocrine regulatory processes. Its endocrine activity is manifested through the synthesis of biologically active substances and hepatokines, the metabolism of hormones, and the production of plasma proteins responsible for hormone transport. The liver synthesizes substances such as insulin-like growth factor 1 (IGF-1), hepcidin, thrombopoietin, angiotensinogen, and fibroblast growth factor 21 (FGF21). These substances participate in the regulation of growth, iron metabolism, hematopoiesis, blood pressure, and glucose and lipid homeostasis. This article analyzes the anatomical and histological foundations of the liver's endocrine activity, the molecular mechanisms of action of major hepatokines, hormonal disturbances associated with liver pathologies, and modern pharmacological approaches, based on scientific literature.
References
1.Rhyu J, Yu R. Newly discovered endocrine functions of the liver. World Journal of Hepatology. 2021;13(11):1611–1628. doi:10.4254/wjh.v13.i11.1611.
2.Quiroz-Aldave JE, et al. From liver to hormones: The endocrine consequences of cirrhosis. World Journal of Gastroenterology. 2024;30(9):1073–1095. doi:10.3748/wjg.v30.i9.1073.
3.Jensen-Cody SO, Potthoff MJ. Hepatokines and metabolism: Deciphering communication from the liver. Molecular Metabolism. 2021;44:101138. doi:10.1016/j.molmet.2020.101138.
4.Frank SJ. Classical and novel GH receptor signaling pathways. Molecular and Cellular Endocrinology. 2021;519:110999. doi:10.1016/j.mce.2020.110999.
5.Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochimica et Biophysica Acta. 2012;1823(9):1434–1443. doi:10.1016/j.bbamcr.2012.01.014.
6.Lim HI, Cuker A. Thrombocytopenia and liver disease: pathophysiology and periprocedural management. Hematology, American Society of Hematology Education Program. 2022;2022(1):296–302. doi:10.1182/hematology.2022000408.
7.Review article: Therapeutic aspects of bile acid signalling in the gut-liver axis. Alimentary Pharmacology & Therapeutics. 2022. doi:10.1111/apt.16602.
8.Sanyal AJ, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. New England Journal of Medicine. 2025;392(21):2089–2099. doi:10.1056/NEJMoa2413258.
9.Harrison SA, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. New England Journal of Medicine. 2024;390:497–509. doi:10.1056/NEJMoa2309000.
10.Guyton AC, Hall JE. Textbook of Medical Physiology. 14th ed. Elsevier; 2021.
11.Rodwell VW, et al. Harper’s Illustrated Biochemistry. 32nd ed. McGraw Hill; 2023.
12.Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clinics in Liver Disease. 2008;12(4):733–746.